Tumor-agnostic genomic and clinical analysis of BRAF fusions identify actionable targets.

Monica F Chen Soo-Ryum Yang Jessica J Tao Antoine Desilets Eli L Diamond Clare J Wilhem Ezra Y Rosen Yixiao Gong Kerry Mullaney Jean Torrisi Robert J Young Romel Somwar Helena Alexandra Yu Mark G Kris Gregory J Riely Maria E Arcila Marc Ladanyi Mark T A Donoghue Neal X Rosen Rona Yaeger Alexander E Drilon Yonina R Murciano-Goroff Michael D Offin

Published in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)

BRAF fusions are found across histologies and represent an emerging actionable target. BRAF fusions have a diverse set of fusion partners. Durable responses to MAPK therapies were seen, particularly in pilocytic astrocytomas. Acquired BRAF fusions were identified after targeted therapy underscoring the importance of post-progression biopsies to optimize treatment at relapse in these patients.

Keyphrases

metastatic colorectal cancer
wild type
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
signaling pathway
peritoneal dialysis
oxidative stress
gene expression
free survival
hepatitis c virus
cell proliferation
genome wide
replacement therapy